Table 1. Participant Characteristics and Their Relation With the Exhaled Nitric Oxide During 16 Weeks of Active Medication Treatment, February 1997 to January 1999.
| Characteristic | Participants | Samples | eNO measurements (ppb) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||
| Total | Triamcinolone | Salmeterol | Placebo | |||||||||
|
|
|
|
|
|||||||||
| N | % | N | % | M | SD | M | SD | M | SD | M | SD | |
| All subjects | 119 | 100 | 480 | 100 | 23.3 | 16.5 | 19.4 | 12.3 | 25.6 | 19.7 | 25.3 | 16.3 |
| Sex | ||||||||||||
| Male | 37 | 31 | 147 | 31 | 20.4 | 20.0 | 12.0 | 6.6 | 24.5 | 25.8 | 23.5 | 18.7 |
| Female | 82 | 69 | 333 | 69 | 24.7 | 14.5 | 22.1 | 12.8 | 26.3 | 15.2 | 26.0 | 15.3 |
| Age | ||||||||||||
| < 20 | 16 | 13 | 47 | 10 | 22.6 | 9.3 | 22.5 | 10.1 | 23.1 | 7.3 | 21.8 | 12.6 |
| 20 to ≤ 40 | 78 | 66 | 338 | 70 | 23.8 | 15.6 | 20.4 | 12.7 | 24.2 | 15.9 | 26.6 | 17.2 |
| > 40 | 25 | 21 | 95 | 20 | 22.1 | 21.5 | 15.2 | 10.5 | 32.0 | 32.0 | 20.3 | 12.0 |
| Minority | ||||||||||||
| Yes | 38 | 32 | 152 | 32 | 24.5 | 19.5 | 19.0 | 11.9 | 34.7 | 27.4 | 21.3 | 13.3 |
| No | 81 | 68 | 328 | 68 | 22.8 | 14.9 | 19.6 | 12.5 | 21.6 | 13.3 | 26.9 | 17.2 |
| Study center | ||||||||||||
| Boston, MA | 25 | 21 | 106 | 22 | 13.9 | 7.2 | 11.6 | 7.3 | 13.8 | 7.0 | 16.0 | 6.2 |
| Denver, CO | 29 | 24 | 130 | 27 | 30.5 | 22.2 | 27.1 | 15.1 | 29.2 | 29.1 | 34.9 | 20.4 |
| Madison, WI | 19 | 16 | 41 | 9 | 22.0 | 13.8 | 14.3 | 9.0 | 23.6 | 13.5 | 25.7 | 15.1 |
| Philadelphia, PA | 20 | 17 | 96 | 20 | 22.5 | 11.5 | 20.0 | 8.4 | 27.6 | 14.1 | 18.6 | 8.1 |
| San Francisco, CA | 23 | 19 | 103 | 21 | 25.4 | 15.0 | 19.4 | 11.0 | 29.0 | 16.0 | 29.2 | 16.4 |
| New York, NY | 3 | 3 | 4 | 1 | 22.3 | 17.8 | 14.9 | 11.5 | 12.3 | — | 47.0 | — |